Agios Pharm Stock Beneish M Score
| AGIO Stock | USD 30.21 0.68 2.30% |
Agios | Beneish M Score |
At this time, it appears that Agios Pharm is an unlikely manipulator. The earnings manipulation may begin if Agios Pharm's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Agios Pharm executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Agios Pharm's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.84
Beneish M Score - Unlikely Manipulator
Agios Pharm Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Agios Pharm's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 2.7 M | 2.8 M |
|
| |||||
| Total Revenue | 25.5 M | 26.8 M |
|
| |||||
| Total Assets | 752.6 M | 937.1 M |
|
| |||||
| Total Current Assets | 574.2 M | 833.8 M |
|
| |||||
| Non Current Assets Total | 178.4 M | 103.3 M |
|
| |||||
| Property Plant Equipment | 21.1 M | 26.4 M |
|
| |||||
| Selling General Administrative | 81.2 M | 119.9 M |
|
| |||||
| Total Current Liabilities | 75.2 M | 68 M |
|
| |||||
| Non Current Liabilities Total | 112.7 M | 58.1 M |
|
| |||||
| Short Term Investments | 428.3 M | 688.7 M |
|
| |||||
| Long Term Investments | 28 M | 29.4 M |
|
| |||||
| Gross Profit Margin | 0.99 | 0.6457 |
|
|
Agios Pharm Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Agios Pharm's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Agios Pharm in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Agios Pharm's degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About Agios Pharm Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
Agios Pharm Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Agios Pharm. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Receivables | 15.3M | 25.4M | 4.4M | 2.2M | 2.8M | 2.7M | |
| Total Revenue | 117.9M | 203.2M | 41.4K | 14.2M | 26.8M | 25.5M | |
| Total Assets | 890.7M | 853.0M | 1.4B | 1.2B | 937.1M | 752.6M | |
| Total Current Assets | 611.7M | 636.7M | 1.1B | 832.8M | 833.8M | 574.2M | |
| Net Debt | 32.7M | (22.2M) | (106.0M) | (53.6M) | (16.2M) | (17.0M) | |
| Short Term Debt | 6.9M | 7.4M | 11.2M | 13.7M | 15.0M | 15.8M | |
| Operating Income | (426.3M) | (316.1M) | (378.4M) | (389.0M) | (391.5M) | (371.9M) | |
| Investments | 103.6M | 90.7M | (548.4M) | 243.3M | 239.6M | 251.6M |
About Agios Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Agios Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agios Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agios Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Agios Pharm Investors Sentiment
The influence of Agios Pharm's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Agios. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Agios Pharm's public news can be used to forecast risks associated with an investment in Agios. The trend in average sentiment can be used to explain how an investor holding Agios can time the market purely based on public headlines and social activities around Agios Pharm. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Agios Pharm's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Agios Pharm's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Agios Pharm's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Agios Pharm.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Agios Pharm in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Agios Pharm's short interest history, or implied volatility extrapolated from Agios Pharm options trading.
Pair Trading with Agios Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.Moving against Agios Stock
| 0.56 | EVO | Evotec SE ADR Earnings Call Tomorrow | PairCorr |
| 0.49 | PCRX | Pacira Pharmaceuticals Financial Report 1st of May 2024 | PairCorr |
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Agios Pharm Piotroski F Score and Agios Pharm Altman Z Score analysis. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for Agios Stock analysis
When running Agios Pharm's price analysis, check to measure Agios Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agios Pharm is operating at the current time. Most of Agios Pharm's value examination focuses on studying past and present price action to predict the probability of Agios Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Agios Pharm's price. Additionally, you may evaluate how the addition of Agios Pharm to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is Agios Pharm's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.33) | Revenue Per Share 0.482 | Quarterly Revenue Growth 0.648 | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.